No abstract

No abstract

No abstract

Objective. To analyze the pharmacoeconomical affordability of antipsychotic drugs (APD) in patients with mental disorders in the structure of dementia at the level of the Gomel region of the Republic of BelarusMaterials and methods. The study used data from the State Register of Medicines of the Republic of Belarus (2022); Clinical Protocol for providing medical care to patients with mental and Behavioral Disorders (2010); website data https://myfin.by about the average pension amount and the minimum subsistence budget of the Gomel region for 2022; data from «State Register of Medicines of the Republic of Belarus» website. For the analysis, the price list for medicines (drugs) of the largest pharmacy chains in Belarus was used, which included the state pharmacies of the Gomel UP «Pharmacy» and commercial pharmacies of the well-known brands in Belarus «ADEL» and «Dobrya Leki». Parameters such as the price affordability of the APD and 4 availability coefficients (Cd) were determined, allowing to correlate the average cost of antipsychotic drugs packaging and the cost of the average daily dose of antipsychotic drugs with the consumer income, as well as the total affordability coefficient (Cd total.).Results. According to all criteria, the most economically affordable drug from the group of typical APD was the generic Haloperidol–Ozone (Ozon, Russia), and the least affordable from the group of atypical ones was the generic Olanzapine (Belmedpreparaty, Republic of Belarus).Conclusion. There is a large selection of APD on the pharmaceutical market of the Gomel region. Generic APD predominate on sale, which are more affordable compared to the original APD. But one should not forget about the advantages of the original drugs – efficiency, safety, innovativeness, reproducibility of the effect and strict quality control, confirmed in clinical trials. However, the genetic drug Olanzapine (Belmedpreparations, RB) is not in any way more superior in terms of affordability, but even inferior to some drugs. This study allowed us to establish that in the Gomel region of the Republic of Belarus, a patient with dementia is provided with a wide choice of APD and the ability to determine the criteria for preference when buying a specific drug.

Background. The analysis of quality of life (QOL) and psycho-emotional disorders (PED) allows not only to monitor the course of the disease, but also to solve many issues arising in the process of treatment. Objective. To study the quality of life and psycho-emotional disorders as a criterion for the effectiveness of therapy in patients with ulcerative colitis (UC). Material and methods. 52 patients with UC and 52 healthy volunteers (HV) were included in the study. The questionnaire for determining the quality of life in patients with inflammatory bowel disease (IBDQ), the hospital anxiety and depression scale (HADS), as well as A.M. Wayne’s questionnaire were used. Results. According to the scale of anxiety (p=0.0000003) and depression (p=0.0000004) the patients with UC had a greater severity of psychological problems before treatment. The therapy led to a decrease in the severity of psychological problems both on the scale of anxiety (p=0.0000007) and that of depression (p=0.0000003) and allowed the UC patients to approach the HV group on the anxiety scale (p=0.20). The comparison of the patients with UC in terms of autonomic dysfunction syndrome (ADS) before and after treatment showed a decrease in the severity of ADS (p=0.0000010). Conclusions. Тhe QOL and PED assessment method can be used to evaluate the effectiveness of therapy in UC patients.